Sumitomo Mitsui Asset Management Company LTD Has $400,000 Stake in United Therapeutics Corporation (UTHR)

Sumitomo Mitsui Asset Management Company LTD continued to hold its position in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, Holdings Channel reports. The institutional investor owned 3,089 shares of the biotechnology company’s stock at the end of the second quarter. Sumitomo Mitsui Asset Management Company LTD’s holdings in United Therapeutics Corporation were worth $400,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its position in United Therapeutics Corporation by 34.9% in the fourth quarter. Teachers Advisors LLC now owns 78,089 shares of the biotechnology company’s stock valued at $11,200,000 after buying an additional 20,204 shares in the last quarter. Creative Planning increased its position in United Therapeutics Corporation by 15.8% in the first quarter. Creative Planning now owns 5,461 shares of the biotechnology company’s stock valued at $739,000 after buying an additional 747 shares in the last quarter. Gulf International Bank UK Ltd increased its position in United Therapeutics Corporation by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 14,100 shares of the biotechnology company’s stock valued at $1,908,000 after buying an additional 180 shares in the last quarter. Capstone Asset Management Co. increased its position in United Therapeutics Corporation by 5.8% in the first quarter. Capstone Asset Management Co. now owns 5,723 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 316 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its position in United Therapeutics Corporation by 8.6% in the first quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the biotechnology company’s stock valued at $1,543,000 after buying an additional 900 shares in the last quarter.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 128.23 on Friday. The stock has a market capitalization of $5.57 billion, a PE ratio of 14.87 and a beta of 1.51. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The company’s 50-day moving average is $130.60 and its 200 day moving average is $135.35.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.42 earnings per share. On average, analysts predict that United Therapeutics Corporation will post $10.70 EPS for the current year.

United Therapeutics Corporation announced that its board has approved a share repurchase program on Thursday, April 27th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 4.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/08/12/sumitomo-mitsui-asset-management-company-ltd-has-400000-stake-in-united-therapeutics-corporation-uthr.html.

UTHR has been the subject of several research analyst reports. HC Wainwright restated a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a research note on Monday, April 17th. Cowen and Company restated a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics Corporation in a research note on Wednesday, April 26th. Wedbush restated an “outperform” rating and issued a $213.00 price objective (down previously from $229.00) on shares of United Therapeutics Corporation in a research note on Thursday, April 27th. Jefferies Group LLC restated an “underperform” rating and issued a $105.00 price objective (down previously from $116.00) on shares of United Therapeutics Corporation in a research note on Friday, April 28th. Finally, ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. Six investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $134.50.

In other United Therapeutics Corporation news, Director Christopher Causey sold 590 shares of the business’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $132.61, for a total transaction of $78,239.90. Following the completion of the transaction, the director now directly owns 3,875 shares of the company’s stock, valued at approximately $513,863.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 2,176 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $127.11, for a total transaction of $276,591.36. Following the transaction, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at $412,471.95. The disclosure for this sale can be found here. Insiders have sold a total of 24,675 shares of company stock valued at $3,181,693 over the last three months. 7.80% of the stock is currently owned by company insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit